Published in Br J Pharmacol on August 01, 1992
Lethal paralysis of Caenorhabditis elegans by Pseudomonas aeruginosa. Proc Natl Acad Sci U S A (1999) 3.19
A new class of organic nitrates: investigations on bioactivation, tolerance and cross-tolerance phenomena. Br J Pharmacol (2009) 1.24
Relaxation mechanisms induced by stimulation of nerves and by nitric oxide in sheep urethral muscle. J Physiol (1994) 1.03
The autophagy enhancer spermidine reverses arterial aging. Mech Ageing Dev (2013) 0.95
Effects of nicorandil as compared to mixtures of sodium nitroprusside and levcromakalim in isolated rat aorta. Br J Pharmacol (1999) 0.81
Effect of intracerebroventricular and intravenous administration of nitric oxide donors on blood pressure and heart rate in anaesthetized rats. Br J Pharmacol (1996) 0.77
Localized administration of sodium nitroprusside enhances its protection against platelet aggregation in stenosed and injured coronary arteries. Tex Heart Inst J (1996) 0.77
Vascular pharmacology of methylene blue in vitro and in vivo: a comparison with NG-nitro-L-arginine and diphenyleneiodonium. Br J Pharmacol (1995) 0.77
Cellular Effects of Pyocyanin, a Secreted Virulence Factor of Pseudomonas aeruginosa. Toxins (Basel) (2016) 0.75
Systemic capillary leak syndrome: is methylene blue the silver bullet? Case Rep Crit Care (2014) 0.75
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem (1976) 903.81
Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev (1991) 42.38
THE AGGREGATION OF BLOOD PLATELETS. J Physiol (1963) 10.00
Selective blockade of endothelium-dependent and glyceryl trinitrate-induced relaxation by hemoglobin and by methylene blue in the rabbit aorta. J Pharmacol Exp Ther (1985) 9.91
Radioimmunoassay for cyclic nucleotides. I. Preparation of antibodies and iodinated cyclic nucleotides. J Biol Chem (1972) 8.24
Femtomole sensitive radioimmunoassay for cyclic AMP and cyclic GMP after 2'0 acetylation by acetic anhydride in aqueous solution. J Cyclic Nucleotide Res (1975) 6.71
Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates. J Pharmacol Exp Ther (1981) 6.71
Correlation between nitric oxide formation during degradation of organic nitrates and activation of guanylate cyclase. Eur J Pharmacol (1987) 5.13
Cyclic GMP synthesis and function. Pharmacol Rev (1987) 4.89
Bioassay of prostacyclin and endothelium-derived relaxing factor (EDRF) from porcine aortic endothelial cells. Br J Pharmacol (1986) 4.23
Relationship between cyclic guanosine 3':5'-monophosphate formation and relaxation of coronary arterial smooth muscle by glyceryl trinitrate, nitroprusside, nitrite and nitric oxide: effects of methylene blue and methemoglobin. J Pharmacol Exp Ther (1981) 3.14
The pharmacology of potassium channels and their therapeutic potential. Trends Pharmacol Sci (1988) 3.10
Oxidation of nitrogen oxides by bound dioxygen in hemoproteins. J Inorg Biochem (1981) 2.77
Measurement of Pseudomonas aeruginosa phenazine pigments in sputum and assessment of their contribution to sputum sol toxicity for respiratory epithelium. Infect Immun (1988) 2.56
Human neutrophils and mononuclear cells inhibit platelet aggregation by releasing a nitric oxide-like factor. Proc Natl Acad Sci U S A (1989) 2.08
Hydrogen peroxide elicits pulmonary arterial relaxation and guanylate cyclase activation. Am J Physiol (1987) 1.72
Nitric oxide (NO) formation from nitrovasodilators occurs independently of hemoglobin or non-heme iron. Eur J Pharmacol (1987) 1.64
Endothelium-derived relaxing factor and atriopeptin II elevate cyclic GMP levels in pig aortic endothelial cells. Br J Pharmacol (1988) 1.45
Purification and structural analysis of pyocyanin and 1-hydroxyphenazine. Eur J Biochem (1986) 1.43
Evidence that cyclic guanosine monophosphate (cGMP) mediates endothelium-dependent relaxation. Eur J Pharmacol (1985) 1.35
Nitric oxide is inactivated by the bacterial pigment pyocyanin. Biochem J (1990) 1.29
Heme-dependent activation of soluble guanylate cyclase by nitric oxide: regulation of enzyme activity by porphyrins and metalloporphyrins. Semin Hematol (1989) 1.26
Interactions of light and sodium nitrite in producing relaxation of rabbit aorta. J Pharmacol Exp Ther (1989) 1.22
Methylene blue inhibits vasodilation of skeletal muscle arterioles to acetylcholine and nitric oxide via the extracellular generation of superoxide anion. J Pharmacol Exp Ther (1990) 1.21
Methylene blue but not changes in cyclic GMP inhibits resting and bradykinin-stimulated production of prostacyclin by pig aortic endothelial cells. Br J Pharmacol (1989) 1.17
Metabolism of glyceryl trinitrate to nitric oxide by endothelial cells and smooth muscle cells and its induction by Escherichia coli lipopolysaccharide. Proc Natl Acad Sci U S A (1992) 1.16
The use of oxyhaemoglobin to explore the events underlying inhibition of platelet aggregation induced by NO or NO-donors. Br J Pharmacol (1990) 1.11
Dissimilarities between methylene blue and cyanide on relaxation and cyclic GMP formation in endothelium-intact intrapulmonary artery caused by nitrogen oxide-containing vasodilators and acetylcholine. J Pharmacol Exp Ther (1986) 1.03
Independent blockade of cerebral vasodilation from acetylcholine and nitric oxide. Am J Physiol (1988) 1.03
Methylene blue and ETYA block flow-dependent dilation in canine femoral artery. Am J Physiol (1986) 0.96
Relationship between cyclic guanosine monophosphate accumulation and relaxation of canine trachealis induced by nitrovasodilators. J Pharmacol Exp Ther (1991) 0.96
Methylene blue selectively inhibits pulmonary vasodilator responses in cats. J Appl Physiol (1985) (1989) 0.95
Direct comparison of the effects of nitroprusside, SIN 1, and various nitrates on platelet aggregation and soluble guanylate cyclase activity. Thromb Res (1988) 0.94
In vivo effect of methylene blue on endothelium-dependent and endothelium-independent dilations of brain microvessels in mice. Circ Res (1988) 0.90
Methylene blue competes with paraquat for reduction by flavo-enzymes resulting in decreased superoxide production in the presence of heme proteins. Arch Biochem Biophys (1988) 0.90
Induction of vascular relaxation by hydroperoxides. Biochem Biophys Res Commun (1986) 0.89
Explanation of the discrepancy between the degree of organic nitrate decomposition, nitrite formation and guanylate cyclase stimulation. Eur Heart J (1988) 0.89
Methylene blue uptake and the reversal of chemically induced methemoglobinemias in human erythrocytes. J Pharmacol Exp Ther (1969) 0.83
Effects of sodium nitrite on ultraviolet light-induced relaxation and ultraviolet light-dependent activation of guanylate cyclase in bovine mesenteric arteries. Biochem Biophys Res Commun (1990) 0.83
Effects of methylene blue on hypoxic cerebral vasodilatation in the rabbit. J Pharmacol Exp Ther (1990) 0.83
Regulation of activity of purified guanylate cyclase from liver that is unresponsive to nitric oxide. Biochem J (1983) 0.82
Direct vasodilators with unknown modes of action: the nitro-compounds and hydralazine. J Cardiovasc Pharmacol (1984) 0.82
Activation of purified soluble guanylate cyclase by arachidonic acid requires absence of enzyme-bound heme. Biochim Biophys Acta (1987) 0.80
Interaction between stimulators of adenylate and guanylate cyclases in human leukocytes, platelets and arteries. Int J Tissue React (1989) 0.80
Involvement of endogenous noradrenaline release in methylene blue-induced contraction of isolated rabbit aorta. Jpn J Pharmacol (1987) 0.77
Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol (1971) 37.53
Release of additional factors in anaphylaxis and its antagonism by anti-inflammatory drugs. Nature (1969) 13.60
An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature (1976) 13.19
Prostaglandins: their disappearance from and release into the circulation. Nature (1967) 8.66
The release and fate of vaso-active hormones in the circulation. Br J Pharmacol (1969) 7.90
Prostaglandins released by the spleen. Nature (1968) 7.61
Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A (1999) 5.96
Indomethacin and aspirin abolish prostaglandin release from the spleen. Nat New Biol (1971) 5.62
Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A (1993) 4.82
Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci U S A (1988) 4.77
Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev (1978) 4.66
Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation. Prostaglandins (1976) 4.54
How safe is general practitioner obstetrics? Lancet (1980) 4.51
Inactivation of prostaglandins by the lungs. Nature (1970) 4.47
Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides. Prostaglandins (1976) 4.44
Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation. Lancet (1977) 4.11
A fluorometric assay for the measurement of nitrite in biological samples. Anal Biochem (1993) 3.92
Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets. Prostaglandins (1977) 3.74
Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis? Lancet (1978) 3.74
The chemical structure of prostaglandin X (prostacyclin). Prostaglandins (1976) 3.63
Effects of anti-inflammatory drugs on prostaglandin biosynthesis. Nat New Biol (1972) 3.54
Inhibition of prostaglandin synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetamidophenol). Nature (1972) 3.30
Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. Pharmacol Rev (2001) 3.29
Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls. N Engl J Med (1979) 3.29
Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium. Thromb Res (1977) 3.28
Prostaglandins, aspirin-like drugs and the oedema of inflammation. Nature (1973) 3.20
A new approach to anti-inflammatory drugs. Biochem Pharmacol (1979) 2.95
Receptor-mediated release of endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells is coupled. Proc Natl Acad Sci U S A (1988) 2.84
Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides. Nature (1976) 2.83
Involvement of nitric oxide in the reflex relaxation of the stomach to accommodate food or fluid. Nature (1991) 2.82
Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature (2002) 2.71
Structure of slow-reacting substance of anaphylaxis from guinea-pig lung. Nature (1980) 2.69
Prostacyclin (PGX) is the endogenous metabolite responsible for relaxation of coronary arteries induced by arachindonic acid. Prostaglandins (1977) 2.67
The metabolism of L-arginine and its significance for the biosynthesis of endothelium-derived relaxing factor: cultured endothelial cells recycle L-citrulline to L-arginine. Proc Natl Acad Sci U S A (1990) 2.63
Measurement of Pseudomonas aeruginosa phenazine pigments in sputum and assessment of their contribution to sputum sol toxicity for respiratory epithelium. Infect Immun (1988) 2.56
Der p 1 facilitates transepithelial allergen delivery by disruption of tight junctions. J Clin Invest (1999) 2.53
The release of prostaglandins and rabbit aorta contracting substance (RCS) from rabbit spleen and its antagonism by anti-inflammatory drugs. Br J Pharmacol (1972) 2.52
Pharmacokinetic function of the pulmonary circulation. Physiol Rev (1974) 2.52
Unstable metabolites of arachidonic acid and their role in haemostasis and thrombosis. Br Med Bull (1978) 2.51
Prostaglandins, oxygen tension and smooth muscle tone. Br J Pharmacol (1972) 2.51
Chemical structure of the morphogen differentiation inducing factor from Dictyostelium discoideum. Nature (1987) 2.49
Intrarenal prostaglandin release attenuates the renal vasoconstrictor activity of angiotensin. J Pharmacol Exp Ther (1973) 2.48
Nasal acquisition of Staphylococcus aureus in a subdivided and mechanically ventilated ward: endemic prevalence of a single staphylococcal strain. J Hyg (Lond) (1970) 2.48
Imidazole: a selective inhibitor of thromboxane synthetase. Prostaglandins (1977) 2.48
The disappearance of bradykinin and eledoisin in the circulation and vascular beds of the cat. Br J Pharmacol Chemother (1967) 2.44
Release of rabbit aorta contracting substance (RCS) and prostaglandins induced by chemical or mechanical stimulation of guinea-pig lungs. Br J Pharmacol (1973) 2.42
Phospholipase A2 activity of guinea-pig isolated perfused lungs: stimulation, and inhibition by anti-inflammatory steroids. Br J Pharmacol (1978) 2.41
The cell wall components peptidoglycan and lipoteichoic acid from Staphylococcus aureus act in synergy to cause shock and multiple organ failure. Proc Natl Acad Sci U S A (1995) 2.36
The contribution of prostaglandin production to contractions of the isolated uterus of the rat. Br J Pharmacol (1973) 2.33
Nitric oxide-mediated hyporeactivity to noradrenaline precedes the induction of nitric oxide synthase in endotoxin shock. Br J Pharmacol (1993) 2.32
A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance (prostaglandin X) which prevents platelet aggregation. Prostaglandins (1976) 2.28
Conversion of angiotensin I to angiotensin II. Nature (1967) 2.26
Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa. Nature (1980) 2.24
Release of prostaglandin E-1 from the rat stomach. Nature (1967) 2.13
FAB-mapping of recombinant-DNA protein products. Biochem Biophys Res Commun (1983) 2.08
Human neutrophils and mononuclear cells inhibit platelet aggregation by releasing a nitric oxide-like factor. Proc Natl Acad Sci U S A (1989) 2.08
Prostaglandins and the mechanism of analgesia produced by aspirin-like drugs. Br J Pharmacol (1973) 2.07
The effects of prostagladin endoperoxides and thromboxane A2 on strips of rabbit coeliac artery and certain other smooth muscle preparations [proceedings]. Br J Pharmacol (1976) 2.06
The release of catechol amines from the adrenal medulla by histamine. Br J Pharmacol Chemother (1965) 2.00
Vascular hyporeactivity to vasoconstrictor agents and hemodynamic decompensation in hemorrhagic shock is mediated by nitric oxide. Proc Natl Acad Sci U S A (1993) 1.96
Rat endothelin is a vasodilator in the isolated perfused mesentery of the rat. Eur J Pharmacol (1989) 1.95
Fate of angiotensin I in the circulation. Nature (1968) 1.94
Endothelial cells metabolize NG-monomethyl-L-arginine to L-citrulline and subsequently to L-arginine. Biochem Biophys Res Commun (1990) 1.94
Aspiration pneumonia: dental and oral risk factors in an older veteran population. J Am Geriatr Soc (2001) 1.93
Metabolism of the angiotensins in isolated perfused tissues. Nature (1969) 1.91
5-hydroxytryptamine in the circulation of the dog. Nature (1967) 1.88
The distribution and metabolism of arachidonic acid in rabbit platelets during aggregation and its modification by drugs. Br J Pharmacol (1977) 1.87
Comparison of the effects of prostacyclin (PGI2), prostaglandin E1 and D2 on platelet aggregation in different species. Prostaglandins (1978) 1.85
Comparison of the vasodepressor effects of prostacyclin and 6-oxo-prostaglandin F1alpha with those of prostaglandin E2 in rats and rabbits. Br J Pharmacol (1978) 1.85
Smokeless tobacco and severe active periodontal disease, NHANES III. J Dent Res (2005) 1.83
Induction of cyclo-oxygenase-2 by cytokines in human pulmonary epithelial cells: regulation by dexamethasone. Br J Pharmacol (1994) 1.82
Proceedings: Prostaglandin generation maintains the smooth muscle tone of the rabbit isolated jejunum. Br J Pharmacol (1972) 1.80
The detection and estimation of bradykinin in the circulating blood. Br J Pharmacol Chemother (1967) 1.80
Pharmacokinetics of aspirin and salicylate in relation to inhibition of arachidonate cyclooxygenase and antiinflammatory activity. Proc Natl Acad Sci U S A (1987) 1.80
Proinflammatory interactions of pyocyanin and 1-hydroxyphenazine with human neutrophils in vitro. J Infect Dis (1990) 1.77
2-Heptyl-4-hydroxyquinoline N-oxide, an antistaphylococcal agent produced by Pseudomonas aeruginosa. J Antimicrob Chemother (1992) 1.71
Self-reported measures for surveillance of periodontitis. J Dent Res (2013) 1.69
Determining dental checkup frequency. J Am Dent Assoc (1999) 1.67
The effects of alteration of blood-volume on the concentration of circulating angiotensin in anaesthetized dogs. J Physiol (1966) 1.66
Partial purification of rabbit aorta contracting substance-releasing factor and inhibition of its activity by anti-inflammatory steroids. Nature (1976) 1.65
The generation from arachidonic acid of rabbit aorta contracting substance (RCS) by a microsomal enzyme preparation which also generates prostaglandins. Br J Pharmacol (1972) 1.65
Co-induction of nitric oxide synthase and cyclo-oxygenase: interactions between nitric oxide and prostanoids. Br J Pharmacol (1995) 1.63
Prostacyclin is a circulating hormone. Nature (1978) 1.60
Synthesis of 6-keto-PGF1alpha by ram seminal vesicle microsomes. Prostaglandins (1977) 1.57
Prostaglandin endoperoxide and thromboxane generating systems and their selective inhibition. Prostaglandins (1976) 1.56
Characterization of the cytoprotective action of peroxynitrite decomposition catalysts. J Biol Chem (1998) 1.55
Pseudomonas aeruginosa pyocyanin and 1-hydroxyphenazine inhibit fungal growth. J Clin Pathol (1999) 1.54
The mode of action of aspirin and similar compounds. J Allergy Clin Immunol (1976) 1.52
Inhibition of the activity of poly(ADP ribose) synthetase reduces ischemia-reperfusion injury in the heart and skeletal muscle. Proc Natl Acad Sci U S A (1997) 1.52
Periodontal disease and risk of fatal coronary heart and cerebrovascular diseases. J Cardiovasc Risk (1999) 1.51
Recognition and management of Kawasaki disease. CMAJ (2000) 1.51
Endothelium-derived relaxing factor reduces platelet adhesion to bovine endothelial cells. Proc Natl Acad Sci U S A (1988) 1.51
Mediation via different receptors of the vasoconstrictor effects of endothelins and sarafotoxins in the systemic circulation and renal vasculature of the anaesthetized rat. Br J Pharmacol (1993) 1.51
Effects on smooth muscle preparations of unidentified vasoactiv peptides from intestine and lung. Nature (1970) 1.51
Eicosanoids in inflammation. Ann Clin Res (1984) 1.50
Osteoclastic inhibition: an action of nitric oxide not mediated by cyclic GMP. Proc Natl Acad Sci U S A (1991) 1.50
Slow-reacting substance of anaphylaxis: purification and characterisation. FEBS Lett (1978) 1.48
Rapid reduction of prostaglandin 15-hydroxy dehydrogenase activity in rat tissues after treatment with protein synthesis inhibitors. Br J Pharmacol (1975) 1.48
Prostaglandins as mediators of inflammation. Adv Prostaglandin Thromboxane Res (1976) 1.48
The effects of non-steroid anti-inflammatory drugs on leukocyte migration in carrageenin-induced inflammation. Eur J Pharmacol (1980) 1.48